‘Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases’ – a 6 center consortium will study if JAKi (filgotinib) is effective and safe in 3 rare disorders — Behcets, inflammatory myositis & IgG4 related disease. https://t.co/UyZM4VNSY2 https://t.co/D2D1tdygS4